Search Results for “EC” – Page 188 – media

sell right, sell well, and sell for a long time

First, the essence of business is market competition, and the market is the battlefield. Business people should have a sales mindset, and salespeople need to have a business perspective. There is a view that sales and business are different positions in pharmaceutical companies, with different responsibilities and assessment standards, and it is difficult to integrate the two positions, so you can focus on your own duties. However, the performance appraisal of most pharmaceutical companies is still stuck in the “butt determines the head” standard, and there is rarely a global vision of “the head decides the butt”. It is beneficial for sales and business to empathize, but it cannot completely resolve all conflicts and disputes. At the time of the transformation of the pharmaceutical industry, cross-disciplinary talents who are both proficient in sales and business are increasingly becoming valuable resources for enterprises to compete for. The business position in the ...
- Source: drugdu
- 75
- October 5, 2024
Digital therapeutics are a big failure

The digital therapeutics industry has evolved and evolved beyond all expectations. In June 2021, Pear Therapeutics, the “first stock of digital therapeutics”, was listed; In April 2023, he filed for bankruptcy and bankruptcy; A year later, Better Therapeutics, another star digital therapeutics company, also fell; Four months ago, Akili chose to sell himself and delist and go private. So far, the three musketeers of overseas digital therapeutics have all fallen. If you count from the listing of Pear, a three-year cycle, the waves will sweep away the heroes. On the surface, the main reason for the collapse of these companies is financial problems, but the deeper reason is the commercialization challenges faced by digital therapeutics. The challenge is that digital therapeutics need to have drug-like efficacy in order to gain market acceptance, but the embarrassment is that prescription digital therapeutics are not drugs per se, but more about using technical ...
- Source: drugdu
- 57
- October 5, 2024
To build China’s own blood brand

In recent years, China’s blood gas analyzer market has shown a strong development trend, especially in critical illness, emergency and surgical scenarios, and the scale has expanded dramatically. At present, the market size of blood gas analysis in China is about 2.7 billion yuan, and the industry growth rate is about 20%. From the perspective of market share, imported brands have the first-mover advantage in R&D and market, according to the data reported by the China Research Institute of Puhua Industry Research Institute, about 80% of the current market share of the domestic blood gas analyzer market is still occupied by imported brands, mainly for Radiometer, Wolfen, Abbott, etc., and domestic brands are mainly represented by the head brand of blood gas. According to the statistics of the bidding network, in the first half of 2024, the scale and demand for blood gas equipment procurement across the country ...
- Source: https://mp.weixin.qq.com
- 82
- October 4, 2024
KIMES BUSAN

Organiser：E&EX Exhibition Company, Korea Time：October 18 – 20, 2024 Address：55 Apec-ro, Haeundae-gu, Busan, 612-704, South Korea Exhibition hall：Busan Exhibition & Convention Center Product range: Medical Equipment: Medical technology equipment, consumables, medical electronic devices, ophthalmic equipment & protective products, surgical instruments, emergency response equipment, hospital, dental, & medical facilities, dental service equipment & disposable medical products, hospital & household disposable medical products, hospital dentistry, medical data processing systems, dental plastic surgery, rehabilitation equipment, etc. In Vitro Diagnostics & Clinical Laboratory Equipment: Endoscopy systems, B-mode ultrasound, examination equipment, ENT treatment instruments, dynamic analysis instruments, total laboratory solutions, clinical diagnostic equipment, diagnostic reagents, precision medicine, POCT (Point-of-Care Testing) home diagnostic devices, clinical laboratory equipment. Rehabilitation & Nursing Supplies: Orthopedic devices, walkers, hearing aids, audio guide systems for visually impaired, manual wheelchairs, electric wheelchairs, crutches, walking aids, massagers, healthcare apparel, fitness equipment, training machines, wrist & ankle braces, wearable neck braces, back braces, ...
- Source: drugdu
- 83
- October 3, 2024
Optimization strategy for production process of RNA targeted drugs

RNA targeted drugs are a completely new category of drugs that are completely different from small molecule drugs and antibody drugs. On the one hand, they can target mRNA, ncRNA, and other intracellular proteins through gene silencing to inhibit their expression and achieve the goal of treating diseases; On the other hand, new generation vaccines and protein replacement therapies can also be developed based on mRNA. RNA targeted drugs are undoubtedly a strategic frontier in biopharmaceutical innovation, with broad potential application scenarios in the future. The production process technology of mRNA industrialization is particularly important for the widespread application and industrialization of mRNA. Based on this, this article will focus on the optimization strategies for the production process of RNA targeted drugs. Stability chemical modification enhances drug safety and efficacy For RNA targeted drugs, chemical modification (excluding tissue targeting ligands) mainly has two basic functions: firstly, chemical modification can significantly ...
- Source: drugdu
- 87
- October 3, 2024
Seven domestic companies have completed a new round of financing, focusing on the fields of cell and gene therapy

In September, several domestic companies focused on the field of cell and gene therapy (CGT) announced progress in financing. This article will share basic information about its 7 companies based on publicly available materials. Xingsairui has successfully completed tens of millions of yuan in angel round financing On September 14th, Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (hereinafter referred to as “Xingsai Ruizhen”) announced the completion of tens of millions of yuan in angel round financing and officially launched the angel+round financing plan! This round of financing is jointly invested by Fosun Pharma’s Rehabilitation Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund. This round of financing will be used for the continuous promotion of core pipelines and platforms, as well as the construction of the company’s team and research and development laboratories. Xingsai Ruizhen was founded in July 2022 and incubated by the New Drug Innovation ...
- Source: drugdu
- 93
- October 3, 2024
“The leader of narcotics” in China, the actual controller may change hands

On September 25, Humanwell Pharmaceutical announced that it had received a “Notification Letter on the Company’s Application for Reorganization” from Wuhan Contemporary Technology Industry Group Co., Ltd. (hereinafter referred to as “Modern Technology”), the controlling shareholder of the company, the day before, and Wuhan Credit Risk Management Financing Guarantee Co., Ltd. and Tianjin Shengcao Law Firm had applied to the Intermediate People’s Court of Wuhan City, Hubei Province for the reorganization of Modern Technology. At present, Humanwell Pharma has not received the documents of the Wuhan Intermediate People’s Court on the acceptance of the above-mentioned application for reorganization, and it is not yet known whether the court will accept it and whether Modern Technology will enter the reorganization procedure in the future. In this regard, many investors took the lead in voting in favor, believing that the replacement of the major shareholder of Modern Technology will be more conducive to ...
- Source: https://mp.weixin.qq.com
- 84
- October 3, 2024
Over 3 billion, Stone Pharmaceutical Group reached a major cooperation

On September 29, Shi Pharma Group signed an exclusive licensing agreement with Jiangsu Conri Pharma on the development and commercialization of JSKN003 in mainland China. JSKN003 is a HER2-targeting bispecific antibody-drug conjugate (ADC) with dual HER2 targeting, giving it stronger internalization induction and bystander killing effects, making it highly active against HER2-expressing tumors. Currently, JSKN003 is undergoing Phase I clinical trials in Australia and Phase I/II and Phase III clinical trials in China. Next, Jinmant Bio (a wholly-owned subsidiary of Chiatai Tianqing Pharmaceutical Group) will be granted exclusive license and sublicensing rights for the development, sales, promised sales, and commercialization of the product. They will bear all clinical development costs and become the sole marketing authorization holder for JSKN003 in Mainland China for that field. According to the agreement, Corning Jerry has the right to receive a total of up to 3.08 billion RMB in upfront and milestone payments, including ...
- Source: https://mp.weixin.qq.com
- 92
- October 2, 2024
The role of brainstem medullary circuit in rapid eye movement sleep and Parkinson’s disease

Mammalian sleep includes rapid eye movement sleep (REMS) and non rapid eye movement sleep (NREM). REMS is also known as paradoxical sleep. The characteristic of NREM is the high amplitude slow wave oscillation of the electroencephalogram, which reflects the synchronous transition of cortical neurons between depolarization rising state and hyperpolarization falling state. In contrast, REM is characterized by an increase in the average firing rate of cortical neurons, rapid oscillations and theta waves in the electroencephalogram, and loss of skeletal muscle activity (muscle tone imbalance). The brainstem’s brainstem is a key structure regulating REMS. Research on cats has shown that the perifocal coeruleus (LC) – α is a crucial region within the pontine tegmentum for inducing REM. Subsequent analysis showed that the subthalatoral nucleus (SLD) of rodents is homologous to LC – α in cats [6,7]. In SLD, inhibiting glutamatergic neurotransmission can reduce REMS levels and alleviate muscle tone ...
- Source: drugdu
- 80
- October 2, 2024
Cell | Ma Kaiyue et al. develop a new method for high-throughput functional identification of mutations

The analysis of pathogenic genetic variations has always been an important challenge in the field of human genetics. Single nucleotide mutations in genes related to Mendelian genetic diseases should be the easiest type of mutation to study in human genetics. However, for many disease genes, the clinical importance of at least half of single nucleotide mutations has not been determined, seriously affecting the diagnostic efficiency of genetic diseases, especially rare genetic diseases. Deep mutational screening (DMS) refers to a research method that generates large-scale gene variations through saturation mutagenesis and then studies genetic variations in cell lines through high-throughput methods. This method can greatly accelerate the diagnosis of genetic diseases and deepen our understanding of the clinical importance of single nucleotide mutations. However, the cost and complexity of current deep mutation screening methods hinder their widespread application in clinical research. On September 25, 2024, Monkol Lek’s team from Yale ...
- Source: BioArt
- 83
- October 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.